Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aspirin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 3/20 | 0.53 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | BLM | P54132 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | ESR1 | P03372 | 1/20 | 0.53 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.53 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.53 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | GGT1 | P19440 | 1/20 | 0.53 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.53 |
| ▸ | MRGPRX4 | Q96LA9 | 9/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aspirin SCHEMBL4160561 | 1.00 | PTGS2 (0.53) | PTGS2KDM4EHSD17B10HPGDALDH1A1 | |
| SCHEMBL4160557 | 0.86 | PTGS2 (0.55) | PTGS2KDM4EHSD17B10HPGDALDH1A1 | |
| SCHEMBL220610 | 0.83 | TMEM97 (0.57) | HPGDMRGPRX4TMEM97NPC1RAB9A | |
| SCHEMBL17986206 | 0.83 | TMEM97 (0.43) | KDM4EHPGDALDH1A1BLMTDP1 | |
| Benzene SCHEMBL16599421 | 0.82 | KDM4E (0.51) | PTGS2KDM4EHSD17B10HPGDALDH1A1 | |
| Ncx-4016 SCHEMBL29813476 | 0.81 | PTGS2 (0.57) | PTGS2KDM4EHSD17B10HPGDALDH1A1 | |
| Ncx-4016 SCHEMBL19524 | 0.81 | PTGS2 (0.57) | PTGS2KDM4EHSD17B10HPGDALDH1A1 | |
| Ncx-4016 SCHEMBL29546681 | 0.81 | PTGS2 (0.57) | PTGS2KDM4EHSD17B10HPGDALDH1A1 | |
| SCHEMBL6400514 | 0.81 | KDM4E (0.52) | PTGS2KDM4EHSD17B10HPGDALDH1A1 | |
| SCHEMBL6401897 | 0.81 | CFD (0.65) | PTGS2KDM4EHSD17B10HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2786749-A1 | Use of nitrooxyderivative of drug for the treatment of muscular dystrophies | Nicox S.A. (FR) | 2014-10-08 | — | — | EP | disclosed |
| EP-1978947-B1 | NITROOXYDERIVATIVES FOR USE IN THE TREATMENT OF MUSCULAR DYSTROPHIES | NICOX SA (FR) | 2014-08-13 | — | — | EP | disclosed |
| US-8802726-B2 | Use of nitrooxyderivative of drug for the treatment of muscular dystrophies | NICOX S.A. (FR) | 2014-08-12 | — | — | US | disclosed |
| CN-101378739-B | Use of nitrooxyderivative of drug for the treatment of muscular dystrophies | NICOX SA | 2014-06-04 | — | — | CN | disclosed |
| US-8575222-B2 | Use of nitrooxyderivatives of drug for the treatment of muscular dystrophies | NICOX S.A. (FR) | 2013-11-05 | — | — | US | disclosed |
| US-20130137765-A1 | USE OF NITROOXYDERIVATIVE OF DRUG FOR THE TREATMENT OF MUSCULAR DYSTROPHIES | NICOX S.A. (FR) | 2013-05-30 | — | — | US | disclosed |
| US-20090093510-A1 | Use of Nitrooxyderivatives of Drug for the Treatment of Muscular Dystrophies | NICOX SA (FR) | 2009-04-09 | — | — | US | disclosed |
| CN-101378739-A | Use of nitrooxyderivative of drug for the treatment of muscular dystrophies | NICOX SA (FR) | 2009-03-04 | — | — | CN | disclosed |
| EP-1978947-A2 | USE OF NITROOXYDERIVATIVE OF DRUG FOR THE TREATMENT OF MUSCULAR DYSTROPHIES | NicOx S.A. (FR) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007088123-A2 | USE OF NITROOXYDERIVATIVE OF DRUG FOR THE TREATMENT OF MUSCULAR DYSTROPHIES | NICOX S.A. (FR) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093510-A1 | Use of Nitrooxyderivatives of Drug for the Treatment of Muscular Dystrophies | TNNC1, CPT1B, SMN1; SMN2 | PTGS2 440/4885PTGS1 292/4885KDM4E 1299/4885 |
| US-20130137765-A1 | USE OF NITROOXYDERIVATIVE OF DRUG FOR THE TREATMENT OF MUSCULAR DYSTROPHIES | TNNC1, CPT1B, SMN1; SMN2 | PTGS2 489/4885PTGS1 248/4885KDM4E 1404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.